Hridaya Shrestha
Overview
Explore the profile of Hridaya Shrestha including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
97
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shrestha H, Radler P, Dennaoui R, Wicker M, Rajbhandari N, Sun Y, et al.
Cell Rep
. 2024 May;
43(5):114202.
PMID: 38733583
Interleukin-6 (IL-6)-class inflammatory cytokines signal through the Janus tyrosine kinase (JAK)/signal transducer and activator of transcription (STAT) pathway and promote the development of pancreatic ductal adenocarcinoma (PDAC); however, the functions...
2.
Radler P, Vistisen K, Triplett A, Dennaoui R, Li Y, Shrestha H, et al.
Sci Rep
. 2021 Oct;
11(1):20775.
PMID: 34675248
We developed a transgenic mouse line that expresses the codon-optimized Flp recombinase under the control of the MMTV promoter in luminal epithelial cells of the mammary gland. In this report,...
3.
Dennaoui R, Shrestha H, Wagner K
Cancer Metastasis Rev
. 2021 Sep;
40(3):803-818.
PMID: 34491463
Although pancreatic cancer remains to be a leading cause of cancer-related deaths in many industrialized countries, there have been major advances in research over the past two decades that provided...
4.
Radler P, Wehde B, Triplett A, Shrestha H, Shepherd J, Pfefferle A, et al.
Nat Commun
. 2021 Jun;
12(1):3742.
PMID: 34145248
Claudin-low breast cancer represents an aggressive molecular subtype that is comprised of mostly triple-negative mammary tumor cells that possess stem cell-like and mesenchymal features. Little is known about the cellular...
5.
Sakamoto K, Radler P, Wehde B, Triplett A, Shrestha H, Ferraiuolo R, et al.
Sci Rep
. 2020 Jan;
10(1):207.
PMID: 31937792
Using an efficient gene targeting approach, we developed a novel mouse line that expresses the tetracycline-controlled transactivator (tTA) from the constitutively active Eef1a1 locus in a Cre recombinase-inducible manner. The...
6.
Wehde B, Radler P, Shrestha H, Johnson S, Triplett A, Wagner K
Cell Rep
. 2018 Nov;
25(8):2192-2207.e5.
PMID: 30463015
Janus kinases (JAKs) and their downstream STAT proteins play key roles in cytokine signaling, tissue homeostasis, and cancer development. Using a breast cancer model that conditionally lacks Janus kinase 1,...
7.
Shrestha N, Shrestha H, Ryu T, Kim H, Simkhada S, Cho Y, et al.
Mol Cells
. 2018 Apr;
41(4):320-330.
PMID: 29629558
δ-Catenin, a member of the p120-catenin subfamily of armadillo proteins, reportedly increases during the late stage of prostate cancer. Our previous study demonstrates that δ-catenin increases the stability of EGFR...
8.
Shrestha H, Ryu T, Seo Y, Park S, He Y, Dai W, et al.
Cell Signal
. 2017 Jan;
31:135-145.
PMID: 28069439
Hakai ubiquitinates and induces endocytosis of the E-cadherin complex; thus, modulating cell adhesion and regulating development of the epithelial-mesenchymal transition of metastasis. Our previous published data show that δ-catenin promotes...
9.
Shrestha H, Yuan T, He Y, Moon P, Shrestha N, Ryu T, et al.
Biochim Biophys Acta
. 2016 Jun;
1863(9):2311-21.
PMID: 27316454
Ubiquitination, a post-translational modification, involves the covalent attachment of ubiquitin to the target protein. The ubiquitin-proteasome pathway and the endosome-lysosome pathway control the degradation of the majority of eukaryotic proteins....
10.
He Y, Ryu T, Shrestha N, Yuan T, Kim H, Shrestha H, et al.
Sci Rep
. 2016 Feb;
6:21207.
PMID: 26883159
Expression of δ-catenin reportedly increases during late stage prostate cancer. Furthermore, it has been demonstrated that expression of EGFR is enhanced in hormone refractory prostate cancer. In this study, we...